nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—ABCB1—Mitomycin—urinary bladder cancer	0.115	0.222	CbGbCtD
Eletriptan—CYP2A6—Fluorouracil—urinary bladder cancer	0.0847	0.164	CbGbCtD
Eletriptan—PTGS1—Etoposide—urinary bladder cancer	0.0604	0.117	CbGbCtD
Eletriptan—CYP3A4—Thiotepa—urinary bladder cancer	0.0522	0.101	CbGbCtD
Eletriptan—ABCB1—Gemcitabine—urinary bladder cancer	0.0331	0.0639	CbGbCtD
Eletriptan—CYP2C9—Fluorouracil—urinary bladder cancer	0.0291	0.0563	CbGbCtD
Eletriptan—HTR7—vas deferens—urinary bladder cancer	0.026	0.294	CbGeAlD
Eletriptan—CYP2C9—Cisplatin—urinary bladder cancer	0.0248	0.0478	CbGbCtD
Eletriptan—ABCB1—Cisplatin—urinary bladder cancer	0.024	0.0464	CbGbCtD
Eletriptan—ABCB1—Etoposide—urinary bladder cancer	0.0236	0.0456	CbGbCtD
Eletriptan—ABCB1—Doxorubicin—urinary bladder cancer	0.0161	0.0311	CbGbCtD
Eletriptan—ABCB1—Methotrexate—urinary bladder cancer	0.0156	0.0301	CbGbCtD
Eletriptan—CYP2D6—Doxorubicin—urinary bladder cancer	0.0152	0.0293	CbGbCtD
Eletriptan—CYP3A4—Etoposide—urinary bladder cancer	0.0141	0.0273	CbGbCtD
Eletriptan—CYP3A4—Doxorubicin—urinary bladder cancer	0.00964	0.0186	CbGbCtD
Eletriptan—CYP2C19—urine—urinary bladder cancer	0.00632	0.0714	CbGeAlD
Eletriptan—CYP2C9—urine—urinary bladder cancer	0.0049	0.0553	CbGeAlD
Eletriptan—CYP3A4—urine—urinary bladder cancer	0.00373	0.0422	CbGeAlD
Eletriptan—CYP2D6—urine—urinary bladder cancer	0.00367	0.0415	CbGeAlD
Eletriptan—CYP2A6—prostate gland—urinary bladder cancer	0.00352	0.0398	CbGeAlD
Eletriptan—CYP2A6—seminal vesicle—urinary bladder cancer	0.00298	0.0337	CbGeAlD
Eletriptan—HTR2B—smooth muscle tissue—urinary bladder cancer	0.00192	0.0217	CbGeAlD
Eletriptan—CYP2A6—vagina—urinary bladder cancer	0.00174	0.0197	CbGeAlD
Eletriptan—HTR7—epithelium—urinary bladder cancer	0.00171	0.0193	CbGeAlD
Eletriptan—HTR1A—renal system—urinary bladder cancer	0.00166	0.0187	CbGeAlD
Eletriptan—HTR7—smooth muscle tissue—urinary bladder cancer	0.00164	0.0186	CbGeAlD
Eletriptan—HTR1B—female reproductive system—urinary bladder cancer	0.00164	0.0186	CbGeAlD
Eletriptan—PTGS1—prostate gland—urinary bladder cancer	0.0016	0.0181	CbGeAlD
Eletriptan—HTR1D—female reproductive system—urinary bladder cancer	0.00159	0.018	CbGeAlD
Eletriptan—HTR7—renal system—urinary bladder cancer	0.00158	0.0179	CbGeAlD
Eletriptan—HTR2B—female reproductive system—urinary bladder cancer	0.00148	0.0167	CbGeAlD
Eletriptan—PTGS1—seminal vesicle—urinary bladder cancer	0.00136	0.0153	CbGeAlD
Eletriptan—HTR2B—vagina—urinary bladder cancer	0.00134	0.0151	CbGeAlD
Eletriptan—HTR7—female reproductive system—urinary bladder cancer	0.00127	0.0143	CbGeAlD
Eletriptan—PTGS1—epithelium—urinary bladder cancer	0.00118	0.0133	CbGeAlD
Eletriptan—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00114	0.0128	CbGeAlD
Eletriptan—CYP2C19—vagina—urinary bladder cancer	0.00112	0.0127	CbGeAlD
Eletriptan—PTGS1—renal system—urinary bladder cancer	0.00109	0.0124	CbGeAlD
Eletriptan—CYP2C9—female reproductive system—urinary bladder cancer	0.000959	0.0108	CbGeAlD
Eletriptan—ABCB1—prostate gland—urinary bladder cancer	0.000949	0.0107	CbGeAlD
Eletriptan—CYP3A4—renal system—urinary bladder cancer	0.000913	0.0103	CbGeAlD
Eletriptan—CYP2D6—renal system—urinary bladder cancer	0.000899	0.0102	CbGeAlD
Eletriptan—PTGS1—female reproductive system—urinary bladder cancer	0.000876	0.0099	CbGeAlD
Eletriptan—HTR2B—lymph node—urinary bladder cancer	0.000866	0.00979	CbGeAlD
Eletriptan—ABCB1—seminal vesicle—urinary bladder cancer	0.000802	0.00907	CbGeAlD
Eletriptan—PTGS1—vagina—urinary bladder cancer	0.000792	0.00895	CbGeAlD
Eletriptan—CYP3A4—female reproductive system—urinary bladder cancer	0.000732	0.00827	CbGeAlD
Eletriptan—CYP2D6—female reproductive system—urinary bladder cancer	0.00072	0.00814	CbGeAlD
Eletriptan—ABCB1—epithelium—urinary bladder cancer	0.000697	0.00788	CbGeAlD
Eletriptan—ABCB1—renal system—urinary bladder cancer	0.000647	0.00731	CbGeAlD
Eletriptan—ABCB1—urethra—urinary bladder cancer	0.000635	0.00718	CbGeAlD
Eletriptan—ABCB1—female reproductive system—urinary bladder cancer	0.000518	0.00585	CbGeAlD
Eletriptan—PTGS1—lymph node—urinary bladder cancer	0.000512	0.00579	CbGeAlD
Eletriptan—ABCB1—vagina—urinary bladder cancer	0.000468	0.00529	CbGeAlD
Eletriptan—ABCB1—lymph node—urinary bladder cancer	0.000303	0.00342	CbGeAlD
Eletriptan—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000221	0.000722	CcSEcCtD
Eletriptan—Asthenia—Gemcitabine—urinary bladder cancer	0.000221	0.00072	CcSEcCtD
Eletriptan—Pharyngitis—Methotrexate—urinary bladder cancer	0.00022	0.000718	CcSEcCtD
Eletriptan—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000219	0.000714	CcSEcCtD
Eletriptan—Weight increased—Doxorubicin—urinary bladder cancer	0.000218	0.000712	CcSEcCtD
Eletriptan—Epistaxis—Epirubicin—urinary bladder cancer	0.000218	0.000711	CcSEcCtD
Eletriptan—Pruritus—Gemcitabine—urinary bladder cancer	0.000218	0.00071	CcSEcCtD
Eletriptan—Nausea—Thiotepa—urinary bladder cancer	0.000217	0.000709	CcSEcCtD
Eletriptan—Urethral disorder—Methotrexate—urinary bladder cancer	0.000217	0.000709	CcSEcCtD
Eletriptan—Weight decreased—Doxorubicin—urinary bladder cancer	0.000217	0.000708	CcSEcCtD
Eletriptan—Sinusitis—Epirubicin—urinary bladder cancer	0.000217	0.000707	CcSEcCtD
Eletriptan—Feeling abnormal—Etoposide—urinary bladder cancer	0.000217	0.000707	CcSEcCtD
Eletriptan—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000216	0.000705	CcSEcCtD
Eletriptan—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000215	0.000701	CcSEcCtD
Eletriptan—Pruritus—Fluorouracil—urinary bladder cancer	0.000214	0.000699	CcSEcCtD
Eletriptan—Drowsiness—Doxorubicin—urinary bladder cancer	0.000214	0.000697	CcSEcCtD
Eletriptan—Visual impairment—Methotrexate—urinary bladder cancer	0.000213	0.000697	CcSEcCtD
Eletriptan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000211	0.00069	CcSEcCtD
Eletriptan—Bradycardia—Epirubicin—urinary bladder cancer	0.000211	0.000689	CcSEcCtD
Eletriptan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000211	0.000687	CcSEcCtD
Eletriptan—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000209	0.000684	CcSEcCtD
Eletriptan—Urticaria—Etoposide—urinary bladder cancer	0.000209	0.000681	CcSEcCtD
Eletriptan—Stomatitis—Doxorubicin—urinary bladder cancer	0.000208	0.00068	CcSEcCtD
Eletriptan—Rhinitis—Epirubicin—urinary bladder cancer	0.000208	0.000678	CcSEcCtD
Eletriptan—Body temperature increased—Etoposide—urinary bladder cancer	0.000208	0.000678	CcSEcCtD
Eletriptan—Abdominal pain—Etoposide—urinary bladder cancer	0.000208	0.000678	CcSEcCtD
Eletriptan—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000208	0.000678	CcSEcCtD
Eletriptan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000207	0.000676	CcSEcCtD
Eletriptan—Tinnitus—Methotrexate—urinary bladder cancer	0.000207	0.000674	CcSEcCtD
Eletriptan—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000206	0.000673	CcSEcCtD
Eletriptan—Asthenia—Cisplatin—urinary bladder cancer	0.000206	0.000672	CcSEcCtD
Eletriptan—Pharyngitis—Epirubicin—urinary bladder cancer	0.000206	0.000671	CcSEcCtD
Eletriptan—Sweating—Doxorubicin—urinary bladder cancer	0.000205	0.000669	CcSEcCtD
Eletriptan—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000205	0.000668	CcSEcCtD
Eletriptan—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000204	0.000666	CcSEcCtD
Eletriptan—Urethral disorder—Epirubicin—urinary bladder cancer	0.000203	0.000663	CcSEcCtD
Eletriptan—Epistaxis—Doxorubicin—urinary bladder cancer	0.000202	0.000658	CcSEcCtD
Eletriptan—Sinusitis—Doxorubicin—urinary bladder cancer	0.0002	0.000654	CcSEcCtD
Eletriptan—Immune system disorder—Methotrexate—urinary bladder cancer	0.0002	0.000653	CcSEcCtD
Eletriptan—Dizziness—Fluorouracil—urinary bladder cancer	0.0002	0.000653	CcSEcCtD
Eletriptan—Visual impairment—Epirubicin—urinary bladder cancer	0.0002	0.000652	CcSEcCtD
Eletriptan—Chills—Methotrexate—urinary bladder cancer	0.000199	0.000649	CcSEcCtD
Eletriptan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000196	0.00064	CcSEcCtD
Eletriptan—Alopecia—Methotrexate—urinary bladder cancer	0.000196	0.000639	CcSEcCtD
Eletriptan—Vomiting—Gemcitabine—urinary bladder cancer	0.000196	0.000638	CcSEcCtD
Eletriptan—Bradycardia—Doxorubicin—urinary bladder cancer	0.000195	0.000637	CcSEcCtD
Eletriptan—Rash—Gemcitabine—urinary bladder cancer	0.000194	0.000633	CcSEcCtD
Eletriptan—Dermatitis—Gemcitabine—urinary bladder cancer	0.000194	0.000633	CcSEcCtD
Eletriptan—Hypersensitivity—Etoposide—urinary bladder cancer	0.000194	0.000632	CcSEcCtD
Eletriptan—Tinnitus—Epirubicin—urinary bladder cancer	0.000193	0.000631	CcSEcCtD
Eletriptan—Headache—Gemcitabine—urinary bladder cancer	0.000193	0.000629	CcSEcCtD
Eletriptan—Flushing—Epirubicin—urinary bladder cancer	0.000192	0.000628	CcSEcCtD
Eletriptan—Vomiting—Fluorouracil—urinary bladder cancer	0.000192	0.000628	CcSEcCtD
Eletriptan—Rhinitis—Doxorubicin—urinary bladder cancer	0.000192	0.000628	CcSEcCtD
Eletriptan—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000191	0.000623	CcSEcCtD
Eletriptan—Rash—Fluorouracil—urinary bladder cancer	0.000191	0.000623	CcSEcCtD
Eletriptan—Dermatitis—Fluorouracil—urinary bladder cancer	0.000191	0.000622	CcSEcCtD
Eletriptan—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00019	0.000621	CcSEcCtD
Eletriptan—Headache—Fluorouracil—urinary bladder cancer	0.00019	0.000619	CcSEcCtD
Eletriptan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000189	0.000618	CcSEcCtD
Eletriptan—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000189	0.000617	CcSEcCtD
Eletriptan—Dysgeusia—Methotrexate—urinary bladder cancer	0.000189	0.000616	CcSEcCtD
Eletriptan—Asthenia—Etoposide—urinary bladder cancer	0.000189	0.000615	CcSEcCtD
Eletriptan—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000188	0.000614	CcSEcCtD
Eletriptan—Immune system disorder—Epirubicin—urinary bladder cancer	0.000187	0.000611	CcSEcCtD
Eletriptan—Back pain—Methotrexate—urinary bladder cancer	0.000187	0.000609	CcSEcCtD
Eletriptan—Chills—Epirubicin—urinary bladder cancer	0.000186	0.000607	CcSEcCtD
Eletriptan—Pruritus—Etoposide—urinary bladder cancer	0.000186	0.000607	CcSEcCtD
Eletriptan—Arrhythmia—Epirubicin—urinary bladder cancer	0.000185	0.000604	CcSEcCtD
Eletriptan—Visual impairment—Doxorubicin—urinary bladder cancer	0.000185	0.000603	CcSEcCtD
Eletriptan—Alopecia—Epirubicin—urinary bladder cancer	0.000183	0.000598	CcSEcCtD
Eletriptan—Nausea—Gemcitabine—urinary bladder cancer	0.000183	0.000596	CcSEcCtD
Eletriptan—Vomiting—Cisplatin—urinary bladder cancer	0.000182	0.000595	CcSEcCtD
Eletriptan—Rash—Cisplatin—urinary bladder cancer	0.000181	0.00059	CcSEcCtD
Eletriptan—Dermatitis—Cisplatin—urinary bladder cancer	0.000181	0.00059	CcSEcCtD
Eletriptan—Diarrhoea—Etoposide—urinary bladder cancer	0.00018	0.000587	CcSEcCtD
Eletriptan—Nausea—Fluorouracil—urinary bladder cancer	0.00018	0.000586	CcSEcCtD
Eletriptan—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000179	0.000584	CcSEcCtD
Eletriptan—Tinnitus—Doxorubicin—urinary bladder cancer	0.000179	0.000584	CcSEcCtD
Eletriptan—Anaemia—Methotrexate—urinary bladder cancer	0.000178	0.000582	CcSEcCtD
Eletriptan—Flushing—Doxorubicin—urinary bladder cancer	0.000178	0.000581	CcSEcCtD
Eletriptan—Flatulence—Epirubicin—urinary bladder cancer	0.000178	0.00058	CcSEcCtD
Eletriptan—Tension—Epirubicin—urinary bladder cancer	0.000177	0.000578	CcSEcCtD
Eletriptan—Dysgeusia—Epirubicin—urinary bladder cancer	0.000177	0.000577	CcSEcCtD
Eletriptan—Nervousness—Epirubicin—urinary bladder cancer	0.000175	0.000572	CcSEcCtD
Eletriptan—Back pain—Epirubicin—urinary bladder cancer	0.000175	0.00057	CcSEcCtD
Eletriptan—Malaise—Methotrexate—urinary bladder cancer	0.000174	0.000568	CcSEcCtD
Eletriptan—Dizziness—Etoposide—urinary bladder cancer	0.000174	0.000567	CcSEcCtD
Eletriptan—Muscle spasms—Epirubicin—urinary bladder cancer	0.000174	0.000566	CcSEcCtD
Eletriptan—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000173	0.000565	CcSEcCtD
Eletriptan—Vertigo—Methotrexate—urinary bladder cancer	0.000173	0.000565	CcSEcCtD
Eletriptan—Leukopenia—Methotrexate—urinary bladder cancer	0.000173	0.000563	CcSEcCtD
Eletriptan—Chills—Doxorubicin—urinary bladder cancer	0.000172	0.000562	CcSEcCtD
Eletriptan—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000171	0.000559	CcSEcCtD
Eletriptan—Nausea—Cisplatin—urinary bladder cancer	0.00017	0.000556	CcSEcCtD
Eletriptan—Alopecia—Doxorubicin—urinary bladder cancer	0.00017	0.000553	CcSEcCtD
Eletriptan—Cough—Methotrexate—urinary bladder cancer	0.000168	0.000549	CcSEcCtD
Eletriptan—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000167	0.000546	CcSEcCtD
Eletriptan—Convulsion—Methotrexate—urinary bladder cancer	0.000167	0.000545	CcSEcCtD
Eletriptan—Vomiting—Etoposide—urinary bladder cancer	0.000167	0.000545	CcSEcCtD
Eletriptan—Anaemia—Epirubicin—urinary bladder cancer	0.000167	0.000544	CcSEcCtD
Eletriptan—Agitation—Epirubicin—urinary bladder cancer	0.000166	0.000541	CcSEcCtD
Eletriptan—Rash—Etoposide—urinary bladder cancer	0.000166	0.000541	CcSEcCtD
Eletriptan—Dermatitis—Etoposide—urinary bladder cancer	0.000166	0.00054	CcSEcCtD
Eletriptan—Headache—Etoposide—urinary bladder cancer	0.000165	0.000537	CcSEcCtD
Eletriptan—Flatulence—Doxorubicin—urinary bladder cancer	0.000165	0.000537	CcSEcCtD
Eletriptan—Arthralgia—Methotrexate—urinary bladder cancer	0.000164	0.000536	CcSEcCtD
Eletriptan—Myalgia—Methotrexate—urinary bladder cancer	0.000164	0.000536	CcSEcCtD
Eletriptan—Tension—Doxorubicin—urinary bladder cancer	0.000164	0.000535	CcSEcCtD
Eletriptan—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000164	0.000534	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000163	0.000532	CcSEcCtD
Eletriptan—Malaise—Epirubicin—urinary bladder cancer	0.000163	0.000531	CcSEcCtD
Eletriptan—Discomfort—Methotrexate—urinary bladder cancer	0.000162	0.000529	CcSEcCtD
Eletriptan—Nervousness—Doxorubicin—urinary bladder cancer	0.000162	0.000529	CcSEcCtD
Eletriptan—Vertigo—Epirubicin—urinary bladder cancer	0.000162	0.000529	CcSEcCtD
Eletriptan—Syncope—Epirubicin—urinary bladder cancer	0.000162	0.000528	CcSEcCtD
Eletriptan—Leukopenia—Epirubicin—urinary bladder cancer	0.000162	0.000527	CcSEcCtD
Eletriptan—Back pain—Doxorubicin—urinary bladder cancer	0.000162	0.000527	CcSEcCtD
Eletriptan—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000161	0.000524	CcSEcCtD
Eletriptan—Palpitations—Epirubicin—urinary bladder cancer	0.000159	0.00052	CcSEcCtD
Eletriptan—Confusional state—Methotrexate—urinary bladder cancer	0.000159	0.000518	CcSEcCtD
Eletriptan—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000159	0.000518	CcSEcCtD
Eletriptan—Cough—Epirubicin—urinary bladder cancer	0.000157	0.000514	CcSEcCtD
Eletriptan—Convulsion—Epirubicin—urinary bladder cancer	0.000156	0.00051	CcSEcCtD
Eletriptan—Nausea—Etoposide—urinary bladder cancer	0.000156	0.000509	CcSEcCtD
Eletriptan—Hypertension—Epirubicin—urinary bladder cancer	0.000156	0.000508	CcSEcCtD
Eletriptan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000155	0.000506	CcSEcCtD
Eletriptan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000154	0.000504	CcSEcCtD
Eletriptan—Anaemia—Doxorubicin—urinary bladder cancer	0.000154	0.000504	CcSEcCtD
Eletriptan—Myalgia—Epirubicin—urinary bladder cancer	0.000154	0.000501	CcSEcCtD
Eletriptan—Arthralgia—Epirubicin—urinary bladder cancer	0.000154	0.000501	CcSEcCtD
Eletriptan—Agitation—Doxorubicin—urinary bladder cancer	0.000153	0.000501	CcSEcCtD
Eletriptan—Anxiety—Epirubicin—urinary bladder cancer	0.000153	0.0005	CcSEcCtD
Eletriptan—Skin disorder—Methotrexate—urinary bladder cancer	0.000153	0.000499	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000153	0.000498	CcSEcCtD
Eletriptan—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000152	0.000497	CcSEcCtD
Eletriptan—Discomfort—Epirubicin—urinary bladder cancer	0.000152	0.000495	CcSEcCtD
Eletriptan—Malaise—Doxorubicin—urinary bladder cancer	0.000151	0.000491	CcSEcCtD
Eletriptan—Dry mouth—Epirubicin—urinary bladder cancer	0.00015	0.00049	CcSEcCtD
Eletriptan—Vertigo—Doxorubicin—urinary bladder cancer	0.00015	0.00049	CcSEcCtD
Eletriptan—Anorexia—Methotrexate—urinary bladder cancer	0.00015	0.00049	CcSEcCtD
Eletriptan—Syncope—Doxorubicin—urinary bladder cancer	0.00015	0.000489	CcSEcCtD
Eletriptan—Leukopenia—Doxorubicin—urinary bladder cancer	0.000149	0.000488	CcSEcCtD
Eletriptan—Confusional state—Epirubicin—urinary bladder cancer	0.000149	0.000485	CcSEcCtD
Eletriptan—Palpitations—Doxorubicin—urinary bladder cancer	0.000148	0.000482	CcSEcCtD
Eletriptan—Oedema—Epirubicin—urinary bladder cancer	0.000147	0.000481	CcSEcCtD
Eletriptan—Hypotension—Methotrexate—urinary bladder cancer	0.000147	0.00048	CcSEcCtD
Eletriptan—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000147	0.000479	CcSEcCtD
Eletriptan—Cough—Doxorubicin—urinary bladder cancer	0.000146	0.000476	CcSEcCtD
Eletriptan—Shock—Epirubicin—urinary bladder cancer	0.000145	0.000473	CcSEcCtD
Eletriptan—Convulsion—Doxorubicin—urinary bladder cancer	0.000145	0.000472	CcSEcCtD
Eletriptan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000144	0.000471	CcSEcCtD
Eletriptan—Hypertension—Doxorubicin—urinary bladder cancer	0.000144	0.00047	CcSEcCtD
Eletriptan—Tachycardia—Epirubicin—urinary bladder cancer	0.000144	0.000469	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000143	0.000468	CcSEcCtD
Eletriptan—Skin disorder—Epirubicin—urinary bladder cancer	0.000143	0.000467	CcSEcCtD
Eletriptan—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000142	0.000465	CcSEcCtD
Eletriptan—Insomnia—Methotrexate—urinary bladder cancer	0.000142	0.000465	CcSEcCtD
Eletriptan—Arthralgia—Doxorubicin—urinary bladder cancer	0.000142	0.000464	CcSEcCtD
Eletriptan—Myalgia—Doxorubicin—urinary bladder cancer	0.000142	0.000464	CcSEcCtD
Eletriptan—Anxiety—Doxorubicin—urinary bladder cancer	0.000142	0.000462	CcSEcCtD
Eletriptan—Paraesthesia—Methotrexate—urinary bladder cancer	0.000141	0.000461	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000141	0.000461	CcSEcCtD
Eletriptan—Discomfort—Doxorubicin—urinary bladder cancer	0.00014	0.000458	CcSEcCtD
Eletriptan—Anorexia—Epirubicin—urinary bladder cancer	0.00014	0.000458	CcSEcCtD
Eletriptan—Dyspnoea—Methotrexate—urinary bladder cancer	0.00014	0.000458	CcSEcCtD
Eletriptan—Somnolence—Methotrexate—urinary bladder cancer	0.00014	0.000457	CcSEcCtD
Eletriptan—Dry mouth—Doxorubicin—urinary bladder cancer	0.000139	0.000454	CcSEcCtD
Eletriptan—Dyspepsia—Methotrexate—urinary bladder cancer	0.000139	0.000452	CcSEcCtD
Eletriptan—Hypotension—Epirubicin—urinary bladder cancer	0.000138	0.000449	CcSEcCtD
Eletriptan—Confusional state—Doxorubicin—urinary bladder cancer	0.000137	0.000448	CcSEcCtD
Eletriptan—Decreased appetite—Methotrexate—urinary bladder cancer	0.000137	0.000446	CcSEcCtD
Eletriptan—Oedema—Doxorubicin—urinary bladder cancer	0.000136	0.000445	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000136	0.000443	CcSEcCtD
Eletriptan—Fatigue—Methotrexate—urinary bladder cancer	0.000136	0.000443	CcSEcCtD
Eletriptan—Pain—Methotrexate—urinary bladder cancer	0.000135	0.000439	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000134	0.000438	CcSEcCtD
Eletriptan—Shock—Doxorubicin—urinary bladder cancer	0.000134	0.000438	CcSEcCtD
Eletriptan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000134	0.000436	CcSEcCtD
Eletriptan—Insomnia—Epirubicin—urinary bladder cancer	0.000133	0.000435	CcSEcCtD
Eletriptan—Tachycardia—Doxorubicin—urinary bladder cancer	0.000133	0.000434	CcSEcCtD
Eletriptan—Skin disorder—Doxorubicin—urinary bladder cancer	0.000132	0.000432	CcSEcCtD
Eletriptan—Paraesthesia—Epirubicin—urinary bladder cancer	0.000132	0.000432	CcSEcCtD
Eletriptan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000132	0.00043	CcSEcCtD
Eletriptan—Dyspnoea—Epirubicin—urinary bladder cancer	0.000131	0.000429	CcSEcCtD
Eletriptan—Somnolence—Epirubicin—urinary bladder cancer	0.000131	0.000427	CcSEcCtD
Eletriptan—Anorexia—Doxorubicin—urinary bladder cancer	0.00013	0.000424	CcSEcCtD
Eletriptan—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00013	0.000423	CcSEcCtD
Eletriptan—Dyspepsia—Epirubicin—urinary bladder cancer	0.00013	0.000423	CcSEcCtD
Eletriptan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000129	0.00042	CcSEcCtD
Eletriptan—Decreased appetite—Epirubicin—urinary bladder cancer	0.000128	0.000418	CcSEcCtD
Eletriptan—Hypotension—Doxorubicin—urinary bladder cancer	0.000127	0.000416	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000127	0.000415	CcSEcCtD
Eletriptan—Fatigue—Epirubicin—urinary bladder cancer	0.000127	0.000414	CcSEcCtD
Eletriptan—Pain—Epirubicin—urinary bladder cancer	0.000126	0.000411	CcSEcCtD
Eletriptan—Constipation—Epirubicin—urinary bladder cancer	0.000126	0.000411	CcSEcCtD
Eletriptan—Urticaria—Methotrexate—urinary bladder cancer	0.000125	0.000408	CcSEcCtD
Eletriptan—Abdominal pain—Methotrexate—urinary bladder cancer	0.000124	0.000406	CcSEcCtD
Eletriptan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000124	0.000406	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000124	0.000405	CcSEcCtD
Eletriptan—Insomnia—Doxorubicin—urinary bladder cancer	0.000123	0.000402	CcSEcCtD
Eletriptan—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000122	0.000399	CcSEcCtD
Eletriptan—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000121	0.000397	CcSEcCtD
Eletriptan—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000121	0.000396	CcSEcCtD
Eletriptan—Somnolence—Doxorubicin—urinary bladder cancer	0.000121	0.000395	CcSEcCtD
Eletriptan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00012	0.000393	CcSEcCtD
Eletriptan—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00012	0.000391	CcSEcCtD
Eletriptan—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000118	0.000387	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000118	0.000384	CcSEcCtD
Eletriptan—Fatigue—Doxorubicin—urinary bladder cancer	0.000117	0.000383	CcSEcCtD
Eletriptan—Urticaria—Epirubicin—urinary bladder cancer	0.000117	0.000382	CcSEcCtD
Eletriptan—Pain—Doxorubicin—urinary bladder cancer	0.000117	0.00038	CcSEcCtD
Eletriptan—Constipation—Doxorubicin—urinary bladder cancer	0.000117	0.00038	CcSEcCtD
Eletriptan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000116	0.00038	CcSEcCtD
Eletriptan—Abdominal pain—Epirubicin—urinary bladder cancer	0.000116	0.00038	CcSEcCtD
Eletriptan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000116	0.000378	CcSEcCtD
Eletriptan—Asthenia—Methotrexate—urinary bladder cancer	0.000113	0.000369	CcSEcCtD
Eletriptan—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000112	0.000366	CcSEcCtD
Eletriptan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000111	0.000364	CcSEcCtD
Eletriptan—Pruritus—Methotrexate—urinary bladder cancer	0.000111	0.000363	CcSEcCtD
Eletriptan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000109	0.000354	CcSEcCtD
Eletriptan—Urticaria—Doxorubicin—urinary bladder cancer	0.000108	0.000353	CcSEcCtD
Eletriptan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000108	0.000352	CcSEcCtD
Eletriptan—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000108	0.000352	CcSEcCtD
Eletriptan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000108	0.000351	CcSEcCtD
Eletriptan—Asthenia—Epirubicin—urinary bladder cancer	0.000106	0.000345	CcSEcCtD
Eletriptan—Pruritus—Epirubicin—urinary bladder cancer	0.000104	0.00034	CcSEcCtD
Eletriptan—Dizziness—Methotrexate—urinary bladder cancer	0.000104	0.00034	CcSEcCtD
Eletriptan—Diarrhoea—Epirubicin—urinary bladder cancer	0.000101	0.000329	CcSEcCtD
Eletriptan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.0001	0.000328	CcSEcCtD
Eletriptan—Vomiting—Methotrexate—urinary bladder cancer	0.0001	0.000327	CcSEcCtD
Eletriptan—Rash—Methotrexate—urinary bladder cancer	9.92e-05	0.000324	CcSEcCtD
Eletriptan—Dermatitis—Methotrexate—urinary bladder cancer	9.91e-05	0.000324	CcSEcCtD
Eletriptan—Headache—Methotrexate—urinary bladder cancer	9.86e-05	0.000322	CcSEcCtD
Eletriptan—Asthenia—Doxorubicin—urinary bladder cancer	9.78e-05	0.000319	CcSEcCtD
Eletriptan—Dizziness—Epirubicin—urinary bladder cancer	9.74e-05	0.000318	CcSEcCtD
Eletriptan—Pruritus—Doxorubicin—urinary bladder cancer	9.64e-05	0.000315	CcSEcCtD
Eletriptan—Vomiting—Epirubicin—urinary bladder cancer	9.36e-05	0.000306	CcSEcCtD
Eletriptan—Nausea—Methotrexate—urinary bladder cancer	9.35e-05	0.000305	CcSEcCtD
Eletriptan—Diarrhoea—Doxorubicin—urinary bladder cancer	9.32e-05	0.000304	CcSEcCtD
Eletriptan—Rash—Epirubicin—urinary bladder cancer	9.29e-05	0.000303	CcSEcCtD
Eletriptan—Dermatitis—Epirubicin—urinary bladder cancer	9.28e-05	0.000303	CcSEcCtD
Eletriptan—Headache—Epirubicin—urinary bladder cancer	9.23e-05	0.000301	CcSEcCtD
Eletriptan—Dizziness—Doxorubicin—urinary bladder cancer	9.01e-05	0.000294	CcSEcCtD
Eletriptan—Nausea—Epirubicin—urinary bladder cancer	8.75e-05	0.000286	CcSEcCtD
Eletriptan—Vomiting—Doxorubicin—urinary bladder cancer	8.66e-05	0.000283	CcSEcCtD
Eletriptan—Rash—Doxorubicin—urinary bladder cancer	8.59e-05	0.00028	CcSEcCtD
Eletriptan—Dermatitis—Doxorubicin—urinary bladder cancer	8.58e-05	0.00028	CcSEcCtD
Eletriptan—Headache—Doxorubicin—urinary bladder cancer	8.54e-05	0.000279	CcSEcCtD
Eletriptan—Nausea—Doxorubicin—urinary bladder cancer	8.09e-05	0.000264	CcSEcCtD
Eletriptan—HTR1E—Signaling Pathways—CXCL8—urinary bladder cancer	2.05e-05	0.000234	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.05e-05	0.000233	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.05e-05	0.000233	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—HRAS—urinary bladder cancer	2.04e-05	0.000232	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.03e-05	0.000232	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.03e-05	0.000232	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CCND1—urinary bladder cancer	2.03e-05	0.000231	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—FGFR3—urinary bladder cancer	2.02e-05	0.00023	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.01e-05	0.00023	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—ESR1—urinary bladder cancer	2.01e-05	0.000229	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—RHOA—urinary bladder cancer	2e-05	0.000228	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—ESR1—urinary bladder cancer	2e-05	0.000228	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2e-05	0.000228	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ENO2—urinary bladder cancer	2e-05	0.000228	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—GPX1—urinary bladder cancer	1.99e-05	0.000226	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.98e-05	0.000226	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—MMP9—urinary bladder cancer	1.97e-05	0.000224	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL2—urinary bladder cancer	1.96e-05	0.000224	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CDKN1A—urinary bladder cancer	1.96e-05	0.000224	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—ESR1—urinary bladder cancer	1.96e-05	0.000223	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—PTEN—urinary bladder cancer	1.96e-05	0.000223	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.95e-05	0.000223	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	1.95e-05	0.000222	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.94e-05	0.000221	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.94e-05	0.000221	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.94e-05	0.000221	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CCND1—urinary bladder cancer	1.91e-05	0.000218	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NCOR1—urinary bladder cancer	1.9e-05	0.000216	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—FGFR3—urinary bladder cancer	1.89e-05	0.000216	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.88e-05	0.000215	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.88e-05	0.000215	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—EP300—urinary bladder cancer	1.87e-05	0.000213	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.87e-05	0.000213	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.87e-05	0.000213	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—MMP9—urinary bladder cancer	1.86e-05	0.000212	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.86e-05	0.000211	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CDKN1A—urinary bladder cancer	1.85e-05	0.000211	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—IL2—urinary bladder cancer	1.85e-05	0.000211	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—PTEN—urinary bladder cancer	1.85e-05	0.00021	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—ESR1—urinary bladder cancer	1.84e-05	0.00021	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	1.83e-05	0.000209	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.83e-05	0.000208	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—SRC—urinary bladder cancer	1.81e-05	0.000207	CbGpPWpGaD
Eletriptan—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.81e-05	0.000207	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.81e-05	0.000206	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.78e-05	0.000203	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CREBBP—urinary bladder cancer	1.76e-05	0.000201	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—EP300—urinary bladder cancer	1.76e-05	0.000201	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.76e-05	0.0002	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CREBBP—urinary bladder cancer	1.75e-05	0.0002	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IGF1—urinary bladder cancer	1.74e-05	0.000199	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—EGFR—urinary bladder cancer	1.73e-05	0.000198	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IGF1—urinary bladder cancer	1.73e-05	0.000197	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—EGFR—urinary bladder cancer	1.72e-05	0.000196	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CREBBP—urinary bladder cancer	1.72e-05	0.000196	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—SRC—urinary bladder cancer	1.71e-05	0.000195	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.7e-05	0.000194	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IGF1—urinary bladder cancer	1.69e-05	0.000193	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—EGFR—urinary bladder cancer	1.69e-05	0.000192	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL2—urinary bladder cancer	1.68e-05	0.000191	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TERT—urinary bladder cancer	1.67e-05	0.000191	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.65e-05	0.000188	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—KRAS—urinary bladder cancer	1.64e-05	0.000187	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—KRAS—urinary bladder cancer	1.63e-05	0.000185	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—MYC—urinary bladder cancer	1.63e-05	0.000185	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CREBBP—urinary bladder cancer	1.61e-05	0.000184	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.61e-05	0.000184	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.6e-05	0.000182	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—RHOA—urinary bladder cancer	1.6e-05	0.000182	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—KRAS—urinary bladder cancer	1.59e-05	0.000182	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IGF1—urinary bladder cancer	1.59e-05	0.000181	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—EGFR—urinary bladder cancer	1.59e-05	0.000181	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—RHOA—urinary bladder cancer	1.59e-05	0.000181	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—EGFR—urinary bladder cancer	1.58e-05	0.000181	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.57e-05	0.000179	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—RHOA—urinary bladder cancer	1.55e-05	0.000177	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.54e-05	0.000175	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—FGFR3—urinary bladder cancer	1.54e-05	0.000175	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—MYC—urinary bladder cancer	1.53e-05	0.000175	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.52e-05	0.000173	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.51e-05	0.000172	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.5e-05	0.000171	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—KRAS—urinary bladder cancer	1.5e-05	0.000171	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—EGFR—urinary bladder cancer	1.5e-05	0.000171	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—KRAS—urinary bladder cancer	1.5e-05	0.000171	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ESR1—urinary bladder cancer	1.49e-05	0.00017	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PPARG—urinary bladder cancer	1.49e-05	0.000169	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—ERBB2—urinary bladder cancer	1.48e-05	0.000168	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—ERBB2—urinary bladder cancer	1.47e-05	0.000167	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.46e-05	0.000166	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—RHOA—urinary bladder cancer	1.46e-05	0.000166	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—ERBB2—urinary bladder cancer	1.44e-05	0.000164	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	1.43e-05	0.000163	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—KRAS—urinary bladder cancer	1.42e-05	0.000162	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CXCL8—urinary bladder cancer	1.4e-05	0.00016	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.4e-05	0.000159	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—HRAS—urinary bladder cancer	1.39e-05	0.000159	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CXCL8—urinary bladder cancer	1.39e-05	0.000159	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—HRAS—urinary bladder cancer	1.38e-05	0.000158	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.38e-05	0.000157	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CXCL8—urinary bladder cancer	1.36e-05	0.000155	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—HRAS—urinary bladder cancer	1.35e-05	0.000154	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—ERBB2—urinary bladder cancer	1.35e-05	0.000154	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.34e-05	0.000153	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL2—urinary bladder cancer	1.34e-05	0.000153	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—TP53—urinary bladder cancer	1.34e-05	0.000152	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.33e-05	0.000152	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL2—urinary bladder cancer	1.33e-05	0.000152	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.33e-05	0.000151	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.31e-05	0.000149	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCND1—urinary bladder cancer	1.31e-05	0.000149	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL2—urinary bladder cancer	1.3e-05	0.000148	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCND1—urinary bladder cancer	1.3e-05	0.000148	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IGF1—urinary bladder cancer	1.29e-05	0.000147	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.28e-05	0.000146	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CXCL8—urinary bladder cancer	1.28e-05	0.000146	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.28e-05	0.000146	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—HRAS—urinary bladder cancer	1.28e-05	0.000146	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.27e-05	0.000145	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—HRAS—urinary bladder cancer	1.27e-05	0.000145	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCND1—urinary bladder cancer	1.27e-05	0.000145	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MMP9—urinary bladder cancer	1.27e-05	0.000144	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.27e-05	0.000144	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.26e-05	0.000144	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.26e-05	0.000144	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CDKN1A—urinary bladder cancer	1.26e-05	0.000144	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TP53—urinary bladder cancer	1.26e-05	0.000144	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PTEN—urinary bladder cancer	1.26e-05	0.000144	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MMP9—urinary bladder cancer	1.26e-05	0.000143	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.25e-05	0.000143	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CDKN1A—urinary bladder cancer	1.25e-05	0.000143	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PTEN—urinary bladder cancer	1.25e-05	0.000143	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.25e-05	0.000142	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.24e-05	0.000141	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.23e-05	0.000141	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.23e-05	0.000141	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MMP9—urinary bladder cancer	1.23e-05	0.00014	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.23e-05	0.00014	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.23e-05	0.00014	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.23e-05	0.00014	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PTEN—urinary bladder cancer	1.23e-05	0.00014	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL2—urinary bladder cancer	1.22e-05	0.000139	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.21e-05	0.000138	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.21e-05	0.000138	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.21e-05	0.000138	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—HRAS—urinary bladder cancer	1.2e-05	0.000137	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EP300—urinary bladder cancer	1.2e-05	0.000137	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.19e-05	0.000136	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	1.19e-05	0.000136	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCND1—urinary bladder cancer	1.19e-05	0.000136	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.19e-05	0.000135	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	1.18e-05	0.000135	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.18e-05	0.000135	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.18e-05	0.000134	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	1.17e-05	0.000133	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EP300—urinary bladder cancer	1.17e-05	0.000133	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—SRC—urinary bladder cancer	1.17e-05	0.000133	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.17e-05	0.000133	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.16e-05	0.000133	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.16e-05	0.000133	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	1.16e-05	0.000132	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.16e-05	0.000132	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	1.16e-05	0.000132	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.15e-05	0.000132	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	0.000131	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	0.000131	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	1.15e-05	0.000131	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	1.14e-05	0.00013	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	0.000127	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.11e-05	0.000127	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.1e-05	0.000126	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	1.1e-05	0.000125	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.09e-05	0.000125	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.09e-05	0.000125	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.09e-05	0.000124	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	0.000124	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.08e-05	0.000123	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	1.07e-05	0.000122	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MYC—urinary bladder cancer	1.05e-05	0.000119	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	1.04e-05	0.000119	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.04e-05	0.000118	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.03e-05	0.000118	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—EP300—urinary bladder cancer	1.03e-05	0.000117	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.03e-05	0.000117	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EGFR—urinary bladder cancer	1.02e-05	0.000117	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTEN—urinary bladder cancer	1.02e-05	0.000116	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.02e-05	0.000116	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	1.02e-05	0.000116	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	1.02e-05	0.000116	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	9.96e-06	0.000114	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	9.92e-06	0.000113	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.92e-06	0.000113	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—EP300—urinary bladder cancer	9.72e-06	0.000111	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	9.67e-06	0.00011	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	9.67e-06	0.00011	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	9.61e-06	0.00011	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	9.57e-06	0.000109	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	9.41e-06	0.000107	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	9.39e-06	0.000107	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	9.36e-06	0.000107	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	9.36e-06	0.000107	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	9.33e-06	0.000106	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PPARG—urinary bladder cancer	9.06e-06	0.000103	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	8.9e-06	0.000101	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.84e-06	0.000101	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	8.84e-06	0.000101	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	8.7e-06	9.92e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	8.66e-06	9.87e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TP53—urinary bladder cancer	8.6e-06	9.8e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	8.54e-06	9.74e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.5e-06	9.68e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	8.36e-06	9.53e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PPARG—urinary bladder cancer	8.33e-06	9.5e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.27e-06	9.43e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PPARG—urinary bladder cancer	8.26e-06	9.42e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	8.22e-06	9.37e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	8.17e-06	9.31e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	8.01e-06	9.13e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	8e-06	9.12e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	7.94e-06	9.05e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	7.86e-06	8.95e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	7.76e-06	8.84e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.69e-06	8.77e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.6e-06	8.67e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.6e-06	8.67e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	7.59e-06	8.65e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	7.51e-06	8.56e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.28e-06	8.3e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	7.17e-06	8.17e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.15e-06	8.15e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	7.13e-06	8.12e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.96e-06	7.93e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.72e-06	7.66e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	6.56e-06	7.47e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	6.5e-06	7.41e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	6.37e-06	7.26e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTEN—urinary bladder cancer	6.22e-06	7.09e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	6.09e-06	6.94e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.07e-06	6.92e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—EP300—urinary bladder cancer	5.93e-06	6.76e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—EP300—urinary bladder cancer	5.79e-06	6.6e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTEN—urinary bladder cancer	5.72e-06	6.52e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTEN—urinary bladder cancer	5.67e-06	6.46e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.45e-06	6.21e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.45e-06	6.21e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.41e-06	6.16e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.23e-06	5.97e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.29e-06	4.89e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.74e-06	4.26e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.56e-06	4.06e-05	CbGpPWpGaD
